Yesterday, Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, held its 2009 Annual Meeting of Shareholders in Knoxville, Tennessee. During the meeting, shareholders voted to re-elect the company’s five members of the Board of Directors, which is composed of three inside directors, and two outside directors. Each Director serves a one-year term.

Dr. Dees, CEO of Provectus commented, “We appreciate the confidence of our shareholders as Provectus continues to achieve its milestones for the development of PV-10 and PH-10. Our recently reported ASCO data support our mission to continue our quest to find a viable, safe and effective treatment for metastatic melanoma, and further our research towards that end. Having completed patient accrual in May for our phase 2 melanoma trial, we look forward to communicating additional results to the scientific community and investors in coming months.”

Dr. Dees continued, “While our primary focus has been directed towards gaining regulatory approval for PV-10 in metastatic melanoma, data from oncology tests in animals indicates the drug has broad spectrum activity towards numerous tumor types. Further, to our knowledge PV-10 is the only intralesionally delivered agent that has been repeatedly demonstrated to induce removal of remote, untreated tumors through a bystander effect.”

Dr. Dees concluded, “While our focus has been on developing PV-10 for metastatic melanoma, our scientific team and investigators are also working on developing PV-10 for other primary and metastatic cancers, such as those of the liver, as well as on PH-10 for atopic dermatitis and psoriasis, both of which are in Phase 2 trials. We look forward to furthering these important studies as well in the upcoming year.”

Provectus also announced that it has updated its website, providing investors and the scientific community with an easy-to-navigate portal to get up-to-date information on the company and its clinical trials. The improved and highly-functional website enables the public to get information they need on Provectus and its development pipeline.